Associated Papers
Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.
Mirza Z et al.
International Journal of Molecular Sciences, 2024
38542393 (PubMed )
Supplement: ijms-25-03419-s001.zip › ijms-2877317-supplementary.pdf
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A et al.
British Journal of Cancer, 2024
Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
36442087 (PubMed )
Supplement: pnas.2211429119.sd02.xlsx › snv_indel
Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood KMT2A-rearranged Acute Leukemia.
Pilheden M et al.
Hemasphere, 2022
36204688 (PubMed )
Supplement: hs9-6-e785-s001.xlsx › S6_Cancer-associated_mutations
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.
Liu T et al.
Nature Communications, 2022
35347147 (PubMed )
Supplement: 41467_2022_29336_MOESM8_ESM.xlsx › Sheet1
Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia.
Petti AA et al.
Blood Cancer Discovery, 2022
35019859 (PubMed )
Supplement: bcd-21-0050_supp.table_1_suppst1.xlsx › D_452198_exome._both_relapses
Mutation signatures of pediatric acute myeloid leukemia and normal blood progenitors associated with differential patient outcomes.
Brandsma AM et al.
Blood Cancer Discovery, 2021
34642666 (PubMed )
Supplement: bloodcandisc-2-484-s002.xlsx › ST1
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H et al.
Annals of Hematology, 2020
32504186 (PubMed )
Supplement: 277_2020_4082_MOESM1_ESM.pdf
Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.
Zhang H et al.
Bmc Cancer, 2020
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC et al.
Blood Advances, 2020
Ras pathway mutation feature in the same individuals at diagnosis and relapse of childhood acute lymphoblastic leukemia.
Zhang HH et al.
Translational Pediatrics, 2020
Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation.
Chougule RA et al.
Npj Genomic Medicine, 2019
appreci8: a pipeline for precise variant calling integrating 8 tools.
Sandmann S et al.
Bioinformatics (oxford, England), 2018
29945233 (PubMed )
Supplement: bty518_supplementary_data_s7.xlsx › TN_Mutations_Filter_2
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M et al.
Leukemia, 2018
29472724 (PubMed )
Supplement: 41375_2018_34_MOESM2_ESM.xlsx › Supplemental_Table_3
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Smith CC et al.
Cancer Discovery, 2015
Select a paper to view details